XILIO
Live / Allowed — Fifth extension granted (statement of use) (as of 12 Nov 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 17 Feb 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97271397
- Mark type
- Word mark
- Filed
- 17 Feb 2022
- Published for opposition
- 14 Feb 2023
- Attorney of record
- Valerie Brennan
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for the treatment of cancer, all of the foregoing excluding pharmaceutical products for sleep disorders, central nervous disorders other than cancers of the central nervous system, and neurological disorders other than cancers of the neurological system
Owner
- XILIO DEVELOPMENT, INC., Waltham, MA, US
- XILIO DEVELOPMENT, INC. CORPORATION, Waltham, MA, US
Prosecution history
- 13 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Nov 2025 — SOU EXTENSION 5 GRANTED
- 06 Oct 2025 — SOU EXTENSION 5 FILED
- 12 Nov 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 06 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Mar 2025 — SOU EXTENSION 4 GRANTED
- 14 Mar 2025 — SOU EXTENSION 4 FILED
- 14 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Sept 2024 — SOU EXTENSION 3 GRANTED
- 25 Sept 2024 — SOU EXTENSION 3 FILED
- 25 Sept 2024 — SOU TEAS EXTENSION RECEIVED
- 28 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Mar 2024 — SOU EXTENSION 2 GRANTED